Hengrui Pharma Advances 2026 Employee Stock Ownership Plan Using Existing A Shares

An update from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) is now available.

Jiangsu Hengrui Pharmaceuticals has approved a 2026 A share employee stock ownership scheme, which will take effect upon shareholder approval and will use existing A shares rather than issuing new equity or options. The programme aims to align the interests of employees, shareholders and the company, enhancing motivation, cohesion and competitiveness to support long-term sustainable growth.

Under Hong Kong listing rules, the scheme falls within provisions governing employee share plans involving existing shares and includes participation by certain directors and the chief executive, technically making it a connected transaction. However, the relevant ratios are below the threshold requiring shareholder approval or additional disclosure, and broader employee participation will proceed on a voluntary, compliant basis for directors, senior management, core personnel and other staff identified by the board.

The most recent analyst rating on (HK:1276) stock is a Buy
with a HK$92.00 price target.
To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock,
see the HK:1276 Stock Forecast page.